Drug intelligence / Profile preview

cinpanemab

Development stage: Discontinued
Lead developer: Biogen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Cinpanemab is a human-derived monoclonal antibody that binds preferentially to aggregated forms of extracellular α-synuclein. It was developed as a potential disease-modifying treatment for Parkinson's disease by targeting and neutralizing pathological α-synuclein aggregates implicated in the progression of the disease. Despite reaching Phase 2 clinical trials, cinpanemab did not demonstrate significant efficacy in slowing disease progression and its development was discontinued[1][2][4][5].

Other names: cinpanemab

Targets

SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on cinpanemab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cinpanemab.

Explore the full profile